Weili Zhao MD, PhD

Weili Zhao, M.D., Ph.D., is a Professor of Hematology and the First Deputy Director of the Shanghai Institute of Hematology, and the Vice President and Associate Chief Physician of the Department of Hematology, at the Shanghai Ruijin Hospital. She is the doctoral supervisor at both Shanghai Jiao Tong University and the University Paris VII. Dr. Zhao is a foreign member of the American Society of Hematology, the Vice President of the Chinese Association of Hematology, the Secretary General of the Chinese Society of Experimental Hematology, and a member of the editorial committee of Pathobiology, Biomarker Research, at the Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and the Clinical Hematology Journal.

Weili Zhao mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular mechanism and targeted therapy of malignant lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis, and cell differentiation involved in lymphoma progression and the availability of targeted agents for treatment.

Dr. Zhao has been awarded the National Award for Science and Technology Progress and Outstanding Achievement Award of Scientific Research from the National Ministry of Education and the HUA XIA Award of Medicine and Technology from the National Ministry of Science and Technology for her research. She is now leading projects granted by the National High Technology Research and Development Program of China, the National Natural Science Foundation of China, and several other events on a provincial level.

Weili Zhao has been honored with New Century Excellent Talents in University by the State Ministry of Education. She has been honored as a Rising Star by the Program for New Century Excellent Talents in University by the State Ministry of Education, and Shu Gang Scholar by the Shanghai Municipal Educational Committee. She has published over 70 articles including those in leading hematology journals like cancer cell, nature genetics, blood, molecular cancer, and more, with total impact factors over 500.